Lv1
78 积分 2022-03-09 加入
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
2个月前
已完结
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
2个月前
已完结
The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045
2个月前
已完结
Estimate of Multiple Myeloma Patients by Line of Therapy in the USA: Population-Level Projections 2020–2025
2个月前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
3个月前
已完结
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study
3个月前
已完结
Current understanding and management of CAR T cell-associated toxicities
4个月前
已完结
SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models
4个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
7个月前
已完结
Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial
7个月前
已完结
皖公网安备34019202002308
